Table 4.
Overview of pharmacologic targeting of necroptosis in experimental rodent pathologies
| Pharmacologic agent | Major finding | References |
|---|---|---|
| Nec-1 | Alleviates ischemic brain injury | [47] |
| Is cardioprotective | [175] | |
| Improves outcome after controlled cortical impact | [176] | |
| Alleviates retinal ischemia reperfusion injury | [177] | |
| Alleviates spinal cord injury pathology in rats | [178] | |
| Alleviates injury in subtotal nephrectomised rats | [179] | |
| Nec-1s | Nec-1s treatment reduces disease severity in experimental autoimmune encephalitis model | [180] |
| NSA | Nec-1 or NSA block death in models of both sporadic and familial ALS (ex vivo) | [181] |
| Dabrafenib | Targets RIPK3 and alleviates acetaminophen-induced liver injury | [182] |
| Upregulated RIPK3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal necrolysis | [183] | |
| Nec-1, SanglifehrinA, 16-86 | Protects from renal ischemia reperfusion injury | [99] |
| Nec-1, cyclosporine A, 3-AB | Protects from remote lung injury after receiving ischemic renal allografts in rats | [101] |